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Tumor immune contexture is a determinant
of anti-CD19 CAR T cell efficacy in large B cell
lymphoma
Nathalie Scholler1,2, Regis Perbost3, Frederick L. Locke 4, Michael D. Jain 4, Sarah Turcan3,
Corinne Danan3, Edmund C. Chang1, Sattva S. Neelapu 5, David B. Miklos 6, Caron A. Jacobson7,
Lazaros J. Lekakis8, Yi Lin9, Armin Ghobadi10, Jenny J. Kim1, Justin Chou1, Vicki Plaks1, Zixing Wang1,
Allen Xue1, Mike Mattie1, John M. Rossi1, Adrian Bot1,11 and Jérôme Galon 3,12 ✉
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient
stratification, we assessed whether tumor immune contexture influenced clinical outcomes after axi-cel. We evaluated the
tumor microenvironment (TME) of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1
phase 2 trial. We uncovered dynamic patterns that occurred within 2 weeks after axi-cel. The biological associations among
Immunoscore (quantification of tumor-infiltrating T cell density), Immunosign 21 (expression of pre-defined immune gene
panel) and cell subsets were validated in three independent LBCL datasets. In the ZUMA-1 trial samples, clinical response and
overall survival were associated with pre-treatment immune contexture as characterized by Immunoscore and Immunosign 21.
Circulating CAR T cell levels were associated with post-treatment TME T cell exhaustion. TME enriched for chemokines (CCL5
and CCL22), γ-chain receptor cytokines (IL-15, IL-7 and IL-21) and interferon-regulated molecules were associated with T cell
infiltration and markers of activity. Finally, high density of regulatory T cells in pre-treatment TME associated with reduced
axi-cel–related neurologic toxicity. These findings advance the understanding of LBCL TME characteristics associated with
clinical responses to anti-CD19 CAR T cell therapy and could foster biomarker development and treatment optimization for
patients with LBCL.

I

mmunotherapies have revolutionized cancer treatment1–4.
Axicabtagene ciloleucel (axi-cel) is a first-in-class anti-CD19
CAR T cell therapy approved for the treatment of relapsed/refractory (r/r) LBCL. In the pivotal ZUMA-1 study (NCT02348216),
the objective response (OR) rate was 83% (58% complete response
(CR) rate); 39% of patients had ongoing responses (median of 27.1
months of follow-up); and grade ≥3 neurologic events (NEs) were
reported in 32% of patients5. Unlike other therapies, such as rituximab6,7, axi-cel has similar efficacy across LBCL subtypes defined
through conventional histological, cytogenetic and molecular prognostic markers7,8. However, ~60% of patients showed primary treatment resistance (~15%) or relapse (~45%) within the first year5,
warranting efforts to understand mechanisms and markers underlying response.
Although the prognostic and predictive roles of the TME9–15
have been described for solid tumors, including for checkpoint
inhibitors16–23, the importance of TME for CAR T cell therapy has
not been established. Taking into account the immune mechanistic nature of the CAR T cell intervention and its proven activity in
patients with diffuse LBCL (DLBCL) with poor or favorable conventional tumor-related prognostic markers, such as bcl-2, bcl-6 and

c-Myc status, we first hypothesized that dynamic patterns developing rapidly in the post-treatment TME distinguish responders
and non-responders and, second, that certain characteristics of the
tumor immune contexture, pre-treatment, may associate with CAR
T cell treatment outcome. Specifically, features of tumor immune
contexture, such as presence of activated or exhausted T cells, infiltration with immune regulatory myeloid cells or other categories of
immune cells, along with gene expression programs that may influence the recruitment, expansion and activity of T cells, may, in fact,
provide a global integrative perspective on whether the given status
of the tumoral process and immune system in a given patient are
favorable or detrimental with respect to benefitting from this treatment modality.
In this study, we systematically investigated a broad range
of immune programs in pre-treatment and post-treatment
biopsy specimens from the ZUMA-1 (refs. 5,24) pivotal study
(Supplementary Table 1 and Extended Data Fig. 1) and uncovered
key TME immune features that associate with clinical outcomes.
When possible, we validated our findings in three independent datasets—namely, treatment-naive biopsy specimens and pre-treatment
specimens from patients enrolled in an ongoing, second-line CAR
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T cell interventional study25 (ZUMA-7; NCT03391466) and from
patients treated with commercial axi-cel at Moffitt Cancer Center26
(Supplementary Tables 2 and 3). These findings advance understanding of the effect of CAR T cell therapy on the TME and the
association with clinical response; they also foster biomarker development and treatment optimization.

Results

TME rapid evolution was a hallmark of clinical response. Best
responses to CAR T cell therapy include rapid CAR expansion
within 7–14 days after infusion and anti-tumor activity typically
evaluated by positron emission tomography–computed tomography (PET–CT) 30 days after infusion. However, the lack of robust
predictive biomarkers for patient stratification and monitoring
remains a major challenge in the field of cellular immunotherapy.
To investigate mechanisms and markers underlying response to
axi-cel, we analyzed and compared pre-treatment TME patterns
that may distinguish responders from non-responders by transcriptomics (Supplementary Tables 4 and 5) and assessed whether
axi-cel triggered changes of the tumor immune contexture detectable before the first evaluation of clinical response, which is typically evaluated 1 month after axi-cel infusion by PET–CT imaging.
Figure 1 and Extended Data Fig. 2 highlight the significant transcriptomics changes in tumor biopsies from pre-treatment to
2 weeks after axi-cel in function of the therapeutic response.
Supplementary Tables 6–8 provide the differential expression of
all the genes assessed before and after axi-cel infusion per therapeutic response type. In responders, the post-treatment evolution
of TME gene expression patterns strikingly differed from those of
non-responders; results were consistent across fresh-frozen (FF;
Fig. 1a,b) and formalin-fixed paraffin-embedded (FFPE) sample
sets (Extended Data Fig. 2) and were independent of pre-treatment
tumor burden (TB; Extended Data Fig. 2a).
Differences spanned all major categories of TME genes,
including innate and adaptive immunity and tumor-related and
stroma-related genes with well-described immune activity or
yet-to-be-determined functionality (Supplementary Tables 6–8).
Responders showed early and rapid elevation of cytotoxic T cell–
related genes (CD8α and granzyme A) and key T cell growth factor
(IL-15) (Fig. 1a,b) as well as interferon (IFN)-γ–regulated immune
checkpoint (IC) encoding genes (CD274, CD276 and CTLA-4),
myeloid-related genes and chemokines (CD14, CD68 and CCL2)
(Extended Data Fig. 2b,c). The evolution of TME gene expression
patterns was vastly different in non-responders, where no increase
in immune-related genes was observed, except for a positive trend
in two pro-inflammatory chemokines (CXCL10 and CXCL11) that
was consistent across FF and FFPE sample sets (Extended Data
Fig. 2d,e) and likely modulated by chemo-conditioning27.
Gene expression across all B cell lineage markers decreased markedly in the TME from responders, including CD19, CD20 (ref. 28), B
cell transcriptional master switch PAX5 (ref. 29) (Fig. 1c), ST6GAL1
(ref. 28), CD22 and transcriptional coactivator POU2AF1 (ref. 30)
(Extended Data Fig. 2f,h). These changes likely reflected axi-cel–
mediated tumor cell clearance given that patients in ZUMA-1 were
largely B cell aplastic at enrollment due to prior rituximab treatment24. In addition, the rapid decrease in gene expression of cancer
testis antigens (CTAs31) was more marked in responders (Extended
Data Fig. 2g), further supporting a rapid evolution toward a reduced
tumor-related signature consistent with the negative correlation in
DLBCL between tumor-infiltrating immune cell signature and B
cell signature (for example, CD19, MS4A1, CD79A and CD79B)32.
Finally, these changes were similar across strata defined by classical
prognostic markers24, and, whereas many immune contexture genes
were strongly upregulated, other immune genes specific for other
immune cell types, including TLR9, HMGB1, ILF3, CSF2, IL3RA
and ICAM4, were not increased post-treatment. Altogether, rapid

and broad changes across adaptive and innate immune programs
and B cell lineage markers in post-treatment TME distinguished
responders from non-responders.
T cell density in TME associated with CR. To validate these findings at the cellular and protein level, we performed multiplex spatial
tissue analyses that combine multiplexed immunohistochemistry (IHC) (Fig. 2a and Extended Data Figs. 3–5), advanced image
analysis and computerized algorithm33. This methodology was
initially developed to create the Immunoscore index20 to quantify
tumor T cell infiltrate and better predict the prognosis of patients
with colorectal cancer than AJCC/UICC TNM staging. Tumor
immune contexture22 characterizes the spatial organization and
density of tumor-infiltrating immune cells and predicts prognosis and response to IC inhibitors in various solid tumors. To adapt
the approach to r/r LBCL and to evaluate additional immune cell
subsets and exhaustion markers, we developed three panels in
addition to Immunoscore T lymphocytes (TLs): Immunoscore
T cell exhaustion (TCE) and TCE+ (with TOX marker) panels
and Immunoscore suppressive cells (SCs) panel (Extended Data
Figs. 3 and 4 and Supplementary Table 9). We demonstrated excellent consistency in quantification of CD3+ and CD8+ T cell densities
between Immunoscore TL and Immunoscore TCE (Extended Data
Fig. 5a,b) and between Immunoscore TCE and Immunoscore TCE+
(Extended Data Fig. 5c). Lastly, the Immunoscore index significantly correlated with tumor infiltration of T cell subsets, including CD3, CD4, CD8 and regulatory T cells (Tregs), but not with
myeloid cell subsets in pre-treatment ZUMA-1 biopsies (Extended
Data Fig. 5d).
Using these panels, we first investigated whether T cell density in
pre-treatment and/or post-treatment TME associated with clinical
outcomes and TB. Immunoscore TCE was measured in ten paired
samples from the ZUMA-1 subset 1 (pre-treatment) and subset 2
(early post-treatment) biopsies. Figure 2b shows that all patients
with low TB and higher helper T (Th) cell density achieved CR
(pink circles in blue squares), and their TME presented a higher
T cell density both pre-therapy and post-therapy to compare with
the TME from patients with high TB (orange symbols). Conversely,
four of five patients with pre-treatment high TB and low T cell
density did not achieve CR. However, one patient with high TB
achieved CR. This patient (orange circle) presented a pre-treatment
intermediary T cell density with post-treatment evolution of TME
to higher density of T cells with activated phenotype (PD1+LAG3−TIM3−) (purple arrow). The results of this small dataset suggest
that post-treatment TME T cell density reflected pre-treatment density and supported CR association with low TB and high cell density
before the first clinical response evaluation.
Lower CAR T levels associated with TME exhausted T cells.
Early studies showed that axi-cel efficacy associates with rapid CAR
T cell expansion in blood5,24 and that the ratio of early CAR T cell
expansion to pre-treatment TB associates with durable response34.
We hypothesized that tumor immune contexture pre-treatment
and early post-treatment could better predict LBCL response
to axi-cel than classical prognostic markers (described in ref. 24;
Supplementary Fig. 3a), including the activated B cell–like (ABC)
cell-of-origin (COO) subtype that predicts a lower overall survival
after standard chemotherapy35,36 than germinal center B cell–like
(GCB) or unclassified subtypes of DLBCL.
We, thus, investigated whether there was an association between
circulating CAR T cell levels and pre-treatment and post-treatment
tumor immune contexture to compare with COO. Tumor immune
contexture was evaluated with Immunoscore TL, TCE+ and
Immunosign 21 (ref. 37). Immunosign 21 profiles the expression of
a pre-defined set of genes associated with T cell and innate immune
programs, effector T cells, ICs, chemokines and IFN-related
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Fig. 1 | Evolution of TME after axi-cel infusion associated with clinical outcomes in ZUMA-1. a, Heat map of gene expression measured by PanCancer
Immune Profiling panel (NanoString) in FF tumor biopsy specimens from patients in ZUMA-1 at baseline (before conditioning and axi-cel infusion,
subset 1, n = 23) and 2–4 weeks after axi-cel infusion (subset 2, n = 13). Among the genes with significant differential expression between pre-treatment
and post-treatment (two-sided t-test without adjustment, P < 0.05), shown genes were selected according to their belonging to a specific TME-related
signature. Patients with CR (n = 18 (12 pre-treatment; six within 2 weeks post-treatment)), PR (n = 7, as noted by asterisks (five pre-treatment, two within
2 weeks post-treatment)) and SD/PD (n = 11 (six pre-treatment, four within 2 weeks post-treatment and one with SD within 4 weeks post-treatment) are
shown. The color range is set to log-transform scaled values. Scaled values are calculated by dividing by the standard deviation. b,c, Expression of T cell–
related genes (b) and B cell lineage genes (c) measured by PanCancer Immune Profiling panel in paired FF biopsy specimens. Values and two-sided t-test
without adjustment in embedded tables. DC, dendritic cell; FOXP3, forkhead box P3; GZMA, granzyme A; IL, interleukin; PAX5, paired box protein 5; PD,
progressive disease; PD-1, programmed cell death protein 1; PR, partial response; SD, stable disease.

molecules (Supplementary Table 5). Immunosign 21 score captured
immune contexture-related features in all (three) independent
datasets analyzed (n = 341 patients; Extended Data Fig. 6) and was
highly correlated with Immunoscore both in the ZUMA-1 subset
and therapy-naive DLBCL from commercial origin (Supplementary
Fig. 1a,b). Immunoscore trended positively with axi-cel response
(Supplementary Fig. 1d–j). In agreement with previous findings
showing similar axi-cel efficacy across disease subtypes and stages6–8,
we found no association between peak CAR T cell levels and COO
(Fig. 3a,b). However, Immunoscore TL index and Immunosign
1874

21 score were significantly lower in the ABC COO subtype
(Fig. 3c,d), suggesting that TME-independent features may contribute to therapeutic response and compensate for TME detrimental
characteristics. In fact, circulating peak CAR levels associated positively with post-treatment TME density of Th cells lacking expression of ICs or of TOX, a known marker of T cell exhaustion28, before
(Fig. 3e, right panel) and after normalization to TB (Extended Data
Fig. 7). Consistent with this observation, the density of cytotoxic T
(Tc) cells expressing all four ICs or TOX+ in combination with any
checkpoint associated negatively with circulating CAR T cell levels
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Fig. 2 | Evolution of T cell subset densities in the TME after axi-cel infusion. a, Representative T cell subset densities measured by Immunoscore TCE/
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five patients with CR with low TB and high Th cell density within the TME pre-infusion and post-infusion (50% of tested patients, two-sided exact Fisher
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programmed cell death protein 1; PR, partial response; SD, stable disease.

in post-treatment TME (Fig. 3e, left panel). These results revealed
an association between poor CAR T cell expansion in blood and
post-treatment TME infiltration with exhausted Tc cells. The
results may indicate that systemic T cell exhaustion, including of
tumor-infiltrating lymphocytes and circulating CAR T cells, associates with a lack of durable response to cell therapy.
Evolution of tumor immune contexture at relapse. We interrogated TME dynamic changes of axi-cel–treated patients developing
secondary treatment resistance after 6 months5. As our dataset of
patients who relapsed after achieving a clinical response to axi-cel
was limited, analyses were performed in matched FF and FFPE
biopsies and in paired samples (n = 7, all patients with longitudinal samples and three patients with both FF and FFPE biopsies).
The TME at relapse evolved toward a global reduction in expression of T cell–related and IC genes, cytokine and IFN-related genes
and major histocompatibility complex (MHC) class I–related
genes compared to early post-treatment TME (Extended Data

Fig. 8a–c). The results were consistent across FF (upper rows), FFPE
(middle rows) and paired (lower rows) biopsies (Extended Data
Fig. 8a,b). Concurrently, an increase in immune counter-regulatory
and tumor-associated markers was observed at relapse, including
genes involved in immune suppression, CTLA-4, CCR4 (ref. 38) and
CCL22 (ref. 39) (Extended Data Fig. 8d; upper row, FFPE biopsies,
and lower row, FF biopsies). TME composition at relapse significantly associated with an increase of CTLA4 gene counts normalized to tumor-infiltrating CD3 gene counts (Extended Data Fig. 8e,f)
but not of FoxP3 gene (Extended Data Fig. 8g,i). Consistent with
these findings, CCL22 gene counts correlated with Treg cell density (Extended Data Fig. 8j) and with CCR4 gene counts in subset
1 (Extended Data Fig. 8k). Unsurprisingly, B cell lineage and CTA
gene expression also significantly increased at relapse (Extended
Data Fig. 9).
Pre-treatment immune contexture associated with survival. We
next addressed whether pre-treatment T cell infiltration in the
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TME correlated with efficacy and survival of patients in ZUMA-1.
Although T cell–related genes and T cell densities only modestly
trended with axi-cel response (Tc density, P = 0.12, and Th density, P = 0.29; Fig. 4a,b), the pre-defined Immunoscore index and
Immunosign 21 significantly correlated with overall survival
(Immunoscore, P = 0.045, and Immunosign 21, P = 0.008; Fig. 4c,d).
Multivariate analyses with clinical and molecular features further
confirmed that survival hazard ratios significantly associated with
Immunoscore and Immunosign 21 (Fig. 4e,f; P = 0.020) as well as
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TB (Fig. 4e,f; P = 0.018/0.03), consistent with previously published
data34. These results emphasized the reliability of Immunoscore and
Immunosign 21 scoring of T cell tumor infiltration across datasets,
but we cannot exclude some inter-dependency between these two
covariates, which will need further exploration using larger datasets.
We next interrogated TME gene expression of chemokines,
cytokines and their receptors for possible association with T cell
genes and T cell density. We analyzed the association between T cell
subsets and chemokine and cytokine expression in pre-treatment
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TME across four independent datasets. Available transcriptomics
data from an ongoing, second-line DLBCL, CAR T cell interventional study25, as well as published results from commercial patients
treated at Moffitt Cancer Center26, were added to ZUMA-1 and
treatment-naive DLBCL datasets already described. The dataset
from the ongoing, second-line DLBLC clinical trial could not be
used to validate associations with clinical outcomes. Chemokines
secreted only by myeloid cells (CXCL9 and CXCL14) or by both
myeloid and T cells (CCL5 and its receptor CCR5), as well as STAT1
gene expression, were directly associated with T cell density in all
four datasets (Fig. 5 and Extended Data Fig. 10). T cell genes (CD3δ,
CD8 and CD4) also correlated with genes encoding cytokines
important for T cell expansion, stemness, viability and differentiation, such as IL-21 Th cells or IL-7, IL-18 and IL-15 produced by
stromal or myeloid cells40,41 (Supplementary Table 10).
We next sought to validate biological associations seen in the
ZUMA-1 cohort using other patient independent datasets extracted
from a second-line DLBCL clinical trial25 and a commercial axi-cel
dataset. In second-line DLBCL, IL-15 and IL-18 correlated with

CD3ε gene expression (Spearman P < 1 × 10−16 and P = 6.6 × 10−16,
respectively). These results were also confirmed in 33 commercial patients. Extended Data Fig. 10a,b shows a robust correlation
between activated T cell markers (GZMA and GNLY) and chemokines (CCL5)26 in the commercial axi-cel datasets. Finally, the analysis of the main immune pathways associated with CR compared
to non-CR in two independent datasets (ZUMA-1 and commercial
axi-cel patients) revealed that, in each patient group, lymphocyte
co-stimulation and leukocyte cell–cell adhesion were associated
with increased fold change, whereas antigen processing and presentation of peptide antigen genes related to M2 macrophages and
myeloid activation (CD206, CD36, CD74, HLA-DM, HLA-DQ,
HLA-DRA, HLA-E and TREM2) were associated with a decrease in
fold change (CR versus non-CR; Extended Data Fig. 10c,d).
Altogether, these data linked key pre-treatment tumor immune
characteristics, including chemokines and γ-chain receptor cytokine expression, to a T cell–involved immune contexture and may
indicate actionable functional pathways to sensitize the TME to
CAR T cell therapy.
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Fig. 5 | T cell subsets in pre-treatment tumor biopsies associated with myeloid-secreted chemokines. a–c, Correlation between CXCL9 gene expression
in pre-treatment tumor biopsies and CD8+ T cell tumor infiltrate measured by Immunoscore TCE panel (a) or CD8A gene expression (b,c) in patients
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Pre-treatment TME T cell subsets associated with survival.
To identify the cell subsets associated with axi-cel outcomes
in the patients in ZUMA-1, we measured the T cell density in
pre-treatment TME with Immunoscore TCE and the expression
1878

levels of B cell lineage genes. The density of CD8+ T cells with
activated phenotype (PD-1+ checkpoint and LAG3+/−TIM3−) was
most significantly associated with OR, contrasting with other CD8+
T cell subsets, including non-activated (no checkpoint expression)
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or exhausted (three checkpoints (PD-1+LAG-3+TIM-3+)) T cells
(Fig. 6a). But the expression levels of B cell lineage genes, including
CD19 (CAR target), CD79b, CD22 and PAX5, were similar across
outcome groups (Extended Data Fig. 9c), whereas the expression
of some CTA genes (PRAME and MAGE-B2 family members) was
more elevated in non-responders (Extended Data Fig. 9d). The cell
density of various myeloid subsets, including CD11b+CD15−CD14+
monocytes and CD68+ macrophages, was greater than the T cell
density in pre-treatment TME (Supplementary Table 11), but the

overall myeloid subset density was not significantly associated with
clinical outcomes (Supplementary Fig. 2)
In contrast, Treg density (CD3+CD8−FoxP3+) was markedly
reduced in patients who developed high-grade (grade ≥3) NEs
after axi-cel, independently of checkpoint expression (Fig. 6b;
P < 0.0001; Supplementary Fig. 3a). Unexpectedly, Treg density
associated positively with TME features favoring axi-cel clinical
response, including high CD8+PD-1+ T cell density (Supplementary
Fig. 3b). Patients with high density of CD8+PD-1+ T cells and
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intermediary/high density of PD-1+ Tregs (≈1/4 of all tested patients)
achieved CR without serious NEs after axi-cel. Most patients
(n = 4/5) with low density of Tregs yet measurable CD8+PD-1+
T cells in pre-treatment TME developed grade ≥3 NEs after axi-cel
(Fig. 6c, purple box; Fisher P = 5.7 × 10−5). Furthermore,
pre-treatment tumor-infiltrating non-activated Th cells positively associated with peak CAR T cell levels, with or without
normalization to TB (Fig. 6de), and pre-treatment Immunoscore
significantly associated with normalized peak CAR T cell levels
(P = 0.028; Fig. 6g). These data suggest that pre-treatment subsets
of tumor-infiltrating lymphocytes, such as activated CD8+ T cells
and Treg cells, associate differentially with efficacy and neurotoxicity after axi-cel.

Discussion

Recent findings suggest that CAR T cell therapy may have curative
potential in select patients with non-Hodgkin’s lymphoma42, but
existing prognostic subgroups do not predict response to axi-cel8.
As preclinical models typically fail to mimic accurately the complex mechanisms of action of immunotherapy, reverse translational
studies were undertaken to identify tumor-related features associated with outcomes to CAR T cell intervention. We performed
comprehensive gene expression analyses on more than 400 patients
with LBCL treated with axi-cel (ZUMA-1, third-line, r/r LBCL;
third-line, relapse LBCL commercial axi-cel patients; patients with
DLBCL enrolled in an ongoing, second-line, CAR T cell study;25 and
treatment-naive patients with DLBCL) as well as multiplex spatial
tissue analysis on 118 ZUMA-1 and treatment-naive patients with
DLBCL. Clinical outcome data were available only for the ZUMA-1
patient datasets; the second-line and treatment-naive patient datasets served as validation for biological associations. We discovered
that tumor immune contexture was associated with, and potentially
a major determinant of, axi-cel clinical efficacy in patients in ZUMA1. The key findings of this study are: (1) rapid change of immune
TME features after axi-cel; (2) CR to CAR T cell treatment associated with pre-treatment TME rich in cytokines and chemokines
that favors T cell involvement; (3) high density of PD-1+LAG-3+/–
T cells in pre-treatment TME associated with OR; (4) low density
of Tregs in pre-treatment TME associated with grade ≥3 neurotoxicity; (5) overall survival associated with high Immunoscore and
Immunosign 21 in pre-treatment TME; and (6) the higher the T cell
exhaustion in post-treatment TME, the lower the circulating CAR
T cell levels, a key correlate of durable response34.
This study demonstrated that TME gene signature evolution
occurs quickly after axi-cel treatment, whereby responders show
rapid upregulation of the T cell–related signature and downregulation of B cell tumor-related markers, defining a dynamic pattern
that separates responders from non-responders within 2 weeks
post-treatment. The early TME gene expression changes that were
observed may serve as a pharmacodynamic marker of response.
Patients with low pre-treatment TB and high T cell involvement
showed higher likelihood of achieving CR, but, when response was
achieved, the TME evolved similarly in small versus large TB. The
pre-specified Immunoscore and Immunosign 21 indexes—pertaining to T cell activity and related immune programs—were associated with overall survival, with clinical follow-up exceeding 1 year.
The density of activated CD8+PD-1+LAG-3+/−TIM-3− T cells was
the TME feature most associated with clinical efficacy. In addition,
pre-treatment TME density of CD3+CD8−FoxP3+ Tregs and related
features associated with lower-grade axi-cel–related neurotoxicity
without a notable association with efficacy, suggesting overall better T cell infiltration and/or a beneficial effect of TME-infiltrating
Tregs on the therapeutic index in this setting possibly related
to the essential role of Tregs in normal tissue protection43,44. At
relapse, the TME acquired an immune-detrimental contexture with
decreased T cell–related signature and increased tumor-associated
1880

and immune counter-regulatory markers45, including CCR4 and
CCL22. Finally, pre-treatment tumor immune contexture associated with T cell presence and activity in TME through chemokines
(for example, CXCL9 and CXCL14) and cytokines (for example,
IL-15, IL-7, IL-18 and IL-21) produced locally (Fig. 5, Extended
Data Fig. 10, Supplementary Fig. 4 and Supplementary Table 10),
which supports the hypothesis that stromal production of T cell–
attractive chemokines and γ-chain receptor cytokines may promote
a T cell–involved TME generally favorable for CAR T cell activity.
The positive association between high density of CD8+PD-1+
T cells in pre-treatment TME and axi-cel response mirrors previous
findings in solid tumors describing response to IC blockade10,15,22,46
and expands the paradigm that immunotherapy47, including CAR
T cell therapy, is favored by an immune-involved TME48,49. Overall
survival also was positively correlated with high Immunoscore
index and Immunosign 21 score. The immune contexture, as measured by the pre-specified gene expression panel Immunosign 21,
has been linked to prediction of response to multiple immunotherapies in multiple cancer types22. It would, thus, be of interest to also
evaluate pre-treatment Immunosign 21 before CAR T cell therapy
for solid tumors.
Furthermore, axi-cel expansion relative to TB, a known robust
correlate of durable efficacy5,34, was positively associated with a
T cell–involved TME at baseline and negatively associated with
exhausted (TOX+) tumor-infiltrating T-cells after axi-cel, providing a key rationale to link pre-treatment and post-treatment tumor
immune contexture and axi-cel performance. In brief, patients with
lower pre-treatment TB, higher density of activated CD8+ T cells
and measurable Tregs within the TME may have a more favorable
clinical evolution in terms of efficacy and toxicity after axi-cel,
and these parameters could be included in the design of future
clinical trials.
This analysis—directed at comparing patients by best response to
axi-cel—has not identified a clear association between pre-treatment
myeloid cell signature in the TME and clinical outcomes or between
COO classification and the response rate to axi-cel in patients with
r/r LBCL. Other studies recently identified a link between specific
myeloid cell signatures and CAR T cell treatment-related toxicities50,51 and durable response, respectively26. The study by Jain et al.26
investigated a distinct question—namely, the effect of myeloid
cells (M-MDSCs) and associated IFN signalling on the process
of relapse in patients who responded to axi-cel, indicating that a
dysregulated myeloid signature may be mechanistically involved
in the process. Immunoscore index and Immunosign 21 were
identified as significant predictors of overall survival after CAR
T cell treatment (Fig. 4), and the latter was correlated with T cell
subset densities (P < 0.005) but not with macrophages or mononuclear subsets (P = 0.69 and P = 0.27, respectively; Extended Data
Fig. 6b) in patients in ZUMA-1. Interestingly, in treatment-naive
and second-line patients with DLBCL, Immunosign 21 did correlate with myeloid subsets (macrophage density, P = 0.0077, and
CD68 gene expression, P = 5.5 × 10−15, respectively; Extended
Data Fig. 6c,d), in addition to CD8 T cells. Furthermore, lower
Immunoscore and Immunosign 21 associated with ABC subtype in
treatment-naive patients, but COO did not correlate with the overall survival of the patients in ZUMA-1 reported in this manuscript
(Figs. 3 and 4). These observations suggest that molecular attributes
of DLBCL subtypes initially influence the TME composition but are
not associated with CAR T cell response. In contrast, the immune
infiltrate, as well as TB, was associated with response to CAR T cells,
and multiple lines of chemotherapy may later modify the composition of the immune infiltrate.
In addition to yielding predictive markers, these findings suggest strategies to overcome treatment resistance in patients with
immune-detrimental TME through local or systemic provision of T cell chemokines, γ-chain receptor cytokines or IFN
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program-stimulating factors, using T cell engineering or combinatorial approaches26,47,52,53. These approaches may include epigenetic
modulators aimed at restoring dysregulated gene expression manifesting through elevated CTAs28,54,55 or TOX, the central regulator
of exhausted CD88+ T cells56, which were found to be negatively
associated with clinical response to axi-cel. Supporting the latter, current CAR T cell generation has a propensity for premature
antigen-induced cell exhaustion and death owing to supraphysiological signaling57.
Our study has several limitations. The only sample dataset with
linked clinical outcomes was the ZUMA-1 patient dataset, and the
sample size for relapse and paired subsets was small. Also, CAR T cell
probes were not included in the study because CAR levels in the TME
were unexpectedly low in biopsies performed 2 weeks after axi-cel.
Earlier immunohistochemical and in situ data have shown that CAR
T cells make up only a very small percentage of intratumoral T cells
5 days or more after axi-cel infusion48. In addition, in two prior studies of tumoral transcriptomics predicting clinical outcomes to CAR
T therapy58,59, clinical benefit was associated with tumor expression
of death receptors, but the content of the transcriptomics panels
employed in this study did not allow us to investigate other possible
tumor cell intrinsic factors, such expression of death receptors. In two
prior studies of tumoral transcriptomics predicting clinical outcomes
to CAR T therapy58,59, both showed the benefit of tumoral expression of death receptors. Finally, the broad deployment of immune
responses after CAR T infusion contrasts with the unexpected low
frequency of detectable autologous CAR T cells in the TME. Reduced
CAR expression on the membrane surface after antigen stimulation
could occur through several mechanisms, hampering detection by
IHC-based and RNA-based methods. Alternative approaches to
detection of CAR T cells in the TME are warranted before translating
the results of this study to other cell therapy modalities.
In conclusion, this study advances understanding of axi-cel
mechanism of action, linking its performance (that is, CAR T cell
efficacy, toxicity and patient survival) to tumor immune contexture
pre-treatment and post-treatment (Supplementary Fig. 4). This
study also highlights a third mechanism of resistance to axi-cel
in third-line DLBCL, in addition to product T cell fitness34 and
target-related evasion60, that is related to the tumor immune microenvironment. Although our sample size was limited, these results,
pending validation, suggest that immune-based therapies with
curative potential, such as axi-cel, should be considered in earlier
lines of therapy where a larger percentage of patients have more
favorable TME features and lower TB, to potentially maximize clinical benefit and curative potential. Given the practical implications,
further TME signature optimization and validation in larger studies
is warranted in LBCL and in other tumor types for which T cell
therapies are being developed.
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Methods

Patient sample collection and preparation. The study protocol for the
single-arm, multicenter, registrational ZUMA-1 study of axi-cel in patients
with relapsed LBCL was previously described5,24. Each study site’s institutional
review board reviewed and approved the study protocol and amendments, and
all patients provided written informed consent. The study was done according
to the International Conference on Harmonisation Good Clinical Practice
guidelines. Patients in the ZUMA-1 study did not receive compensation for their
participation. Eligible patients had histologically confirmed LBCL and refractory
disease, defined as progressive or stable disease as best response to most recent
chemotherapy regimen or disease progression or relapse within 12 months after
autologous stem cell transplantation5,24. Patients received axi-cel at a target dose of
2.0 × 106 CAR T cells per kilogram5,24. Tumor biopsy specimens from patients in
ZUMA-1 (Extended Data Fig. 1) were collected at baseline (before conditioning
chemotherapy (pre-lymphodepletion)) and after axi-cel infusion. The largest
group of samples (40%) was from lymph nodes, but no significant differences
in the TME composition between tumor originating from lymph nodes versus
other origins were found by principal component analysis (PCA) of all gene
expression for FFPE baseline samples (Extended Data Fig. 1b). Patients with
samples collected before axi-cel infusion are referred to throughout the manuscript
as subset 1, early after CAR T cell infusion (days 7–14) as subset 2 and later at
relapse as subset 3 (Extended Data Fig. 1c). Of note, not all patient samples are on
all figures. Inclusion of samples was based on the following. (1) In addition to the
informed consent statement for trial participation and primary analysis, consent
for exploratory analysis was required, which reduces the amount from the total
number of patients enrolled in the ZUMA-1 phase 2 pivotal trial. (2) Remaining
sample available for testing. (3) Samples that passed quality control (QC) for any
given platform, as described below. After sample quality was controlled for, a total
of 135 baseline and post-treatment biopsy specimens from 51 patients in ZUMA-1
with LBCL were analyzed for this study. The patient characteristics and clinical
outcomes analyzed in this study were compared to those of the overall ZUMA-1
population. No significant differences were found (t-test P values for age = 1; P
value for sex = 0.318; P value for best response = 0.175; P value for disease type
comparison = 0.664; P value for International Prognostic Index (IPI) = 0.846; P
value for more than three prior lines of therapy = 0.664; P value for CAR T cell
levels = 0.854). All post-treatment biopsy specimens were acquired between days 7
and 14, except for a specimen collected at week 4 from a patient with stable disease.
Subset 1 (baseline) includes 46 patients, with nine patients with FF biopsies, 19
patients with FFPE biopsies and 18 patients with both types of biopsies. Subset
2 (post-treatment) includes 28 patients, with nine patients with FF biopsies, ten
patients with FFPE biopsies and nine patients with both. Subset 3 (relapse) includes
seven patients, with one patient with FF biopsies, four patients with FFPE biopsies
and two patients with both (Extended Data Fig. 1d). The patient characteristics and
clinical outcomes described in this study were consistent with those observed in
the overall ZUMA-1 cohort (Supplementary Table 1). Best response was evaluated
within 2 years of axi-cel infusion for patients enrolled in ZUMA-1 phases 1 and 2
(cohorts 1 and 2) and within 6 months of axi-cel infusion for patients enrolled in
ZUMA-1 phase 2 (cohort 3). NEs in ZUMA-1 were graded according to Common
Terminology Criteria for Adverse Events, version 4 (refs. 5,24).
Three independent datasets were also included in this study (Supplementary
Table 3)—namely, 67 biopsy specimens from treatment-naive patients with
DLBCL (collected at time of diagnosis), 252 biopsy specimens from patients
with r/r DLBCL in an ongoing open-label, second-line, interventional study
(NCT03391466; study is still blinded to outcomes) and 33 biopsy specimens from
axi-cel commercial patients treated at Moffitt Cancer Center26. Baseline tumor
samples were analyzed by targeted transcriptomics (Immuno-Oncology 360) for
the 252 second-line patients and 33 axi-cel commercial patients treated at Moffitt
Cancer Center.
Gene expression profiling. Gene expression profiling was performed using three
gene panels (Supplementary Table 4) on 89 biopsy specimens from ZUMA-1
patient subsets 1, 2 and 3. Twenty-four patients had longitudinal biopsy specimens
(baseline/post-infusion, n = 17; baseline/post-infusion/relapse, n = 6; baseline/
relapse, n = 1). Clinical research tests, including Immunoscore TL (consensus
Immunoscore assay CD3 and CD8), Immunoscore TCE (CD3, CD8, FoxP3, PD-1,
LAG-3 and TIM-3), Immunoscore TCE+ (CD3, CD8, FoxP3, PD-1, LAG-3, TIM-3,
TOX ND and EZH2), Immunoscore SC (CD11b, CD14, CD15, CD68, S100A9 and
LOX-1) and Immunosign 21 (Supplementary Table 4), were performed in a Clinical
Laboratory Improvement Amendments–certified laboratory (HalioDx). For
ZUMA-1 pre/post–axi-cel comparisons, biopsy specimens were analyzed using the
PanCancer Immune Profiling Panel. For pre-treatment (baseline) analyses, biopsy
specimens were analyzed using the PanCancer Immune + Immunosign Gene
Panel. Slide sets were prepared from each FFPE block by cutting ten consecutive
4-µm sections, which were further immobilized on Superfrost Plus slides. One
slide was used for hematoxylin and eosin (H&E) staining; two consecutive slides
were used for Immunoscore TL (automatic staining CD3/CD8, BenchMark XT);
and four or five consecutive slides were used for RNA extraction and NanoString
profiling. Slides were de-identified and tracked using a unique number for each
pre-analytical step, and two workflows per patient were performed
Nature Medicine | www.nature.com/naturemedicine
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Sample QC. QC at various steps was implemented to remove samples or data that
failed to meet requirements. Incoming FFPE blocks were visually inspected to
assess block quality or to determine whether sufficient material remained. Tissue
sections were assessed for defects in section quality. H&E stains were assessed for
image quality and necrosis by a pathologist. Slides with more than 95% necrotic
tissues were not stained. Because most DLBCL biopsy specimens lacked an
identifiable invasive margin, the percentage of tumor content was not part of the
initial tissue selection for staining. After multiplex IHC panels, technical criteria—
including tissue staining QC of tissue sections, image QC for blurry areas or
artifacts and digital pathology QC (specificity, intensity, detection sensitivity and
detection of tumor areas)—were used to select study samples. For RNA sequencing,
samples that did not meet input requirements or had extensive degradation were
eliminated. Suitable samples were then assessed for library preparation metrics,
sequencing QC (Q30 > 70%) and analysis QC (10 million assigned reads obtained).
For NanoString analyses, samples that did not have sufficient input and any
samples flagged as failing raw data QC or normalization QC by NCounter software
during analysis were removed. The starting number of samples and final number
of samples that passed all QC metrics and were, therefore, included in the various
analyses are stated below for the respective assays.
Antibody validation. The CD3 (HDX1) and CD8 (HDX2) primary antibody
performances have been established and validated for the Immunoscore
colon cancer test (CLIA and CE-IVD marked test) and are produced by
Veracyte. Commercial antibody characteristics are listed in Supplementary
Table 12 and include CD3 (1 μg ml−1)61, CD8 (1 μg ml−1)61, PD1 (1/8,000,
0.125 μg ml−1; https://cdn.origene.com/datasheet/um800091.pdf)62, LAG3 (1/400,
1.95 μg ml−1; https://www.cellsignal.com/products/primary-antibodies/lag3-d2
g4o-xp-rabbit-mab/15372)63, TIM3 (1/400, 0.04 μg ml−1; https://www.cellsignal.
com/products/primary-antibodies/tim-3-d5d5r-xp-rabbit-mab/45208)32,
FoxP3 (1/100, 5 μg ml−1; https://www.thermofisher.com/antibody/product/
FOXP3-Antibody-clone-236A-E7-Monoclonal/14-4777-82)64, TOX (1/100,
10 μg ml−1; https://www.abcam.com/tox-antibody-nan448b-ab237009.
html)65, EZH2 (1/800, 0.53 μg ml−1; https://www.cellsignal.com/products/
primary-antibodies/ezh2-d2c9-xp-rabbit-mab/5246)66, LOX1 (1/800,
1.25 μg ml−1; https://www.merckmillipore.com/FR/fr/product/Anti-LOX-1-clone9E12.1,MM_NF-MABS186), CD68 (1/1,000, 0.7 μg ml−1; https://www.abcam.
com/cd68-antibody-epr20545-ab213363.html)67, CD11b (1/200, 0.5 μg ml−1;
https://www.cellsignal.com/products/primary-antibodies/cd11b-itgam-d6
x1n-rabbit-mab/49420)68, CD14 (1/50, 0.07 μg ml−1; https://www.cellmarque.
com/antibodies/CM/2066/CD14_EPR3653)69, CD15 (1/100, 5 μg ml−1; https://
www.bdbiosciences.com/en-us/search-results?searchKey=555400)70 and S100A9
(1/16,666, 0.06 μg ml−1; https://cdn.origene.com/datasheet/um800066.pdf).
The primary antibodies were selected to cross-react on human tissues and were
recommended by the suppliers for IHC on FFPE tissues. Supporting literature
regarding antibody specificity is found in the suppliers’ documentation. For
Immunoscore testing, the specificity of the selected primary antibodies was
verified using human tonsil as positive tissue for targeted immune biomarkers.
Simplex IHC protocol was further optimized for each biomarker using DLBCL
FFPE samples before the multiplex IHC.
Targeted transcriptomics analysis and Immunosign scores. RNA was extracted
from frozen or fixed biopsy specimens using a QIAGEN RNeasy kit or QIAGEN
RNeasy FFPE extraction kit, respectively. Annotations from the pathologist
performing the H&E staining were used to guide removal of normal tissue from
the slides by microdissection before RNA extraction, which occurred after tissue
deparaffinization and lysis. Each RNA extraction was independently quantified
(NanoDrop) and qualified (Agilent Bioanalyzer). Degradation assessment was
quantified as the percentage of RNA fragments smaller than 300 base pairs
(Agilent Bioanalyzer, RNA 6000 Nano Kit). The qualification assessments (RNA
quantity or quality) were informative but not used as acceptance criteria, except for
samples that did not meet the minimum RNA input requirements. When needed,
overdiluted RNA was concentrated using the clean-up approach from QIAGEN
RNeasy kit protocols. Good sample quality was defined as <50% of RNA fragments
of 50–300 base pairs in size. All the extracted RNA was tested independent of the
concentration or the degradation rate. One RNA QC sample was included in each
testing run as a positive control for extraction.
RNA expression profiling was performed using one standard panel (PanCancer
human Immuno-Oncology 360 Panel) and two custom NanoString panels
(Supplementary Tables 4 and 5). After data normalization and analysis, a high
or low Immunosign score cutoff was arbitrarily defined as the 25th percentile
of the observed scores among samples, and gene expression levels for 21
pre-specified genes were compositely scored as Immunosign 21 (Extended Data
Fig. 6a). High scores indicated expression of immune-related genes that were
potentially associated with tumor response. Univariate and multivariate analyses
were performed to determine whether pre-treatment tumor or immune features
influence clinical responses.
The determination of the COO subtypes of DLBCL was performed following
transcriptomic71 (lymph2Cx) or proteomic (Hans algorithm) methods in place in
patient care centers.
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IHC, Immunoscore TL, Immunoscore TCE, Immunoscore TCE+ and
Immunoscore SC. H&E staining allowed preliminary tissue evaluation for FFPE
block QC. Slides were scanned with the NanoZoomer-XR to generate digital
images (×20). A pathologist identified the tumor area and provided qualitative
and semi-quantitative assessments. CD19 IHC staining (LE-CD19) was scored by
composite H-score (0–5 = ‘No’; 6–300 = ‘Yes’).
Results of the Immunoscore TL assay, which measures the density of CD8+
Tc cells and CD3+ T cells in resected or biopsied cancer samples, are expressed
as a score determined by a percentile approach72. Consecutive FFPE slices (4 µm)
were immunostained using a qualified BenchMark XT in accordance with the
following workflow and reagents: antigen retrieval; staining with primary antibody
CD3, HDX2 or CD8, HDX1 or HalioDx/Veracyte SAS; detection with a secondary
antibody using an ultraView Universal DAB Detection Kit (Roche, 760-500); and
counterstaining using the hematoxylin and bluing reagent Hematoxylin II (Roche,
790-2208). Control slides were systematically included in each staining run to
permit QC of the obtained measurements. After coverslipping, slides were scanned
with the NanoZoomer-XR to generate digital images (×20) and were analyzed
in parallel by two independent, qualified operators. CD3 and CD8 IHC staining
(Extended Data Fig. 3ab) was scored and converted into an Immunoscore using the
HalioDx/Veracyte algorithm.
The Immunoscore TCE (CD3, CD8, FoxP3, PD-1, LAG-3 and TIM-3;
Extended Data Fig. 3c and Supplementary Table 9) and SC (CD11b, CD14, CD15,
CD68, S100A9 and LOX-1; Extended Data Fig. 3d and Supplementary Table 9)
sequential IHC panels were performed to measure 14 myeloid and T cell subsets
using FFPE biopsy specimens. The Immunoscore TCE+ sequential IHC panel
(CD3, CD8, FoxP3, PD-1, LAG-3, TIM-3, TOX and EZH2; Extended Data Figs.
3 and 4 and Supplementary Table 9) was performed to measure 37 T cell subsets
(Supplementary Table 9). Phenotype consistency between TCE and TCE+ stainings
was demonstrated using eight samples that overlapped between the TCE and TCE+
panels (Extended Data Fig. 5c). Successive stainings were performed on the same
slide using a Leica Bond RX and the antibodies listed in Supplementary Table
13. For the TCE and TCE+ panels, signal detection was performed using MACH
2 rabbit universal horseradish peroxidase polymer or MACH 2 mouse universal
horseradish peroxidase polymer as secondary antibody and ImmPACT AMEC
Red substrate detection. Counterstaining of cellular nuclei using hematoxylin
was performed at the end of each staining workflow. One control slide was
systematically included in each run to permit QC of the obtained measurements
using qualitative acceptance criteria (specificity, staining location (nucleus/
membrane), cell type and lack of background or unspecific staining). After each
individual staining, coverslipping was performed automatically by the workstation
CTM6 with aqueous mounting. Slides were scanned with the NanoZoomer-XR
(×20), and a visual QC permitted qualification. Coverslips were carefully removed
from slides using a warm water bath; slides were AMEC-destained by ethanol; and
antibodies were stripped with denaturing solution. Each sample was analyzed using
a HalioDx Digital Pathology Platform. Images were aligned with Brightplex-fuse
(in-house software). Tumor areas were identified using annotation tools;
subsequently, positively stained cells were detected and quantified in the selected
regions of interest using HALO software (Indica Labs). Phenotypes of stained cells
were visually verified according to expected staining and analyzed with Brightplex
MultiplexR (in-house software).
Statistics and reproducibility. No valid data were excluded from the analyses.
All statistical analysis and graphics were performed using R (version 4.0.3)
and R Studio (version 1.3.1093) software. t-tests, exact Fisher tests, Wilcoxon
tests, Kruskal–Wallis tests and Spearman correlation tests were evaluated
using R built-in stats library. Heat maps were performed using the library
ComplexHeatmap (version 2.4.3); box plots and scatter plots were performed
using the library ggpubr (version 0.4.0); Cox proportional hazards regression was
performed using the library survival (version 3.2.7); and Kaplan–Meier plots were
performed using the library survminer (version 0.4.8). For each box plot, the lower
bond, center and higher bond of the box are 25th (Q1), 50th (median) and 75th
(Q3) percentiles, respectively. The boundaries of the whiskers are found within the
1.5 interquartile range (IQR) value (where IQR = Q3 − Q1). From above the upper
quartile (Q3), a distance of 1.5 times the IQR is measured out, and a whisker (max.
whisker) is drawn up to the largest observed data point from the dataset that falls
within this distance. Similarly, a distance of 1.5 times the IQR is measured out
below the lower quartile (Q1), and a whisker (min.whisker) is drawn down to the
lowest observed data point from the dataset that falls within this distance. The box
plot statistics are shown in Supplementary Table 14.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

Clinical response data and demographics/patient characteristics for ZUMA-1
are available in Supplementary Table 1, and demographics/patient characteristics
for ZUMA-7 are available in Supplementary Table 2. Patient-related data not
included in the paper were generated as part of clinical trials and may be subject to
patient confidentiality. Any data and materials that can be shared will be released
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via a material transfer agreement. Correlations between pre-treatment gene
expression of cytokines and cytokine-responsive transcription factors and T cell
markers in ZUMA-1 patients who achieved CR are available in Supplementary
Table 6. Correlations between pre-treatment gene expression of cytokines and
cytokine-responsive transcription factors and T cell markers in ZUMA-1 patients
who achieved OR are available in Supplementary Table 7. Correlations between
pre-treatment gene expression of cytokines and cytokine-responsive transcription
factors and T cell markers in ZUMA-1 patients who did not achieve CR or OR
are available in Supplementary Table 8. Differential gene expression by pathway
in pre-treatment tumor biopsies of axi-cel responders versus non-responders
are available in Supplementary Table 12. The NanoString data from ZUMA-1
patients discussed in this publication have been deposited in the National Center
of Biotechnology Information Gene Expression Omnibus (GEO) and are accessible
through GEO Series with the following accession number and access code:
GSE197977 and chuhmyuidlwrdiv.
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Extended Data Fig. 1 | Characterization of ZUMA-1 tumour biopsy specimens analysed in this study. a, Number of tumour biopsies per known anatomic
location from Zuma 1 patients analysed in the manuscript; b, PCA of Zuma 1 baseline biopsies (subset 1) with the two first principal components of all
gene expression. Data are colored by biopsy origin; lymph node, blue, n = 12; not lymph node origin (as indicated in a), yellow, n = 7; unknown origin, red,
n = 10; c. Number of Zuma 1 patients analyzed in the manuscript, classification per subset, and overview of the longitudinal biopsies; d. Number of Zuma
1 patients analyzed in the manuscript with FF and/or FFPE biopsies classified per subset. FF, fresh frozen; FFPE, formalin-fixed paraffin embedded; PCA,
principal component analysis.
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Extended Data Fig. 2 | See next page for caption.
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Extended Data Fig. 2 | Evolution of the tumour infiltrate in ZUMA-1 patients after axi-cel infusion associated with clinical outcomes independently
of tumour burden. a, Heatmap of gene expression measured by PanCancer Immune Profiling panel (NanoString) in FFPE tumour biopsy specimens
pretreatment (subset 1, n = 29) or posttreatment (subset 2, n = 14) from Zuma 1 patients with high or low tumour burden at pretreatment. Among the
genes with significant differential expression between pre and post treatment (Two-sided t.test without adjustment, p.value <0.05), shown genes were
selected according to their belonging to a specific TME related signature. Patients with CR and low tumour burden, n = 17 (Subset 1, n = 12; Subset 2,
n = 5); with CR and high tumour burden, n = 15 (Subset 1, n = 8; Subset 2, n = 7); without CR and low tumour burden, n = 2 (Subset 1); without CR and
high tumour burden, n = 9 (Subset 1, n = 7; Subset 2, n = 2). PR (n=4, as noted by asterisks [2 pretreatment; 2 within 2 weeks posttreatment]. The
color range is set to log-transform scaled values. Scaled values are calculated by dividing by the standard deviation. b-e, Gene expression measured
by PanCancer Immune Profiling panel in paired specimens; (two sided t.test without adjustment); b,c, T-cell functional genes (b) and myeloid- and
cytokine-related genes (c) in FF biopsies; d,e, CXCL10 and CXCL11 genes in FF (d) vs. FFPE (e) biopsies. *P < 0.1 and ***P < 0.01. f,g, Volcano plots
of gene expression from pre- vs. posttreatment biopsies of patients with SD/PD or CR/PR (as indicated) for B-cell lineage (f) and CTA genes (g).
The plots were constructed using log2(fold change) and log10 (P values) for all genes. Red dots represent the top differentially expressed genes with
P<0.01. h, Comparative gene expression of B-cell lineage selected markers in pre- vs posttreatment biopsies. *P < 0.1 and **P < 0.05.(Two-sided t.test
without adjustment). axi-cel, axicabtagene ciloleucel; CCL, chemokine ligand; CR, complete response; CTA, cancer testis antigen; CTLA-4, cytotoxic T
lymphocyte–associated protein 4; CXCL, chemokine C-X-C motif ligand; DC, dendritic cell; MAGE-B2, melanoma-associated antigen B2; PD, progressive
disease; PD-L1, programmed death-ligand 1; PF: Fresh frozen; FFPE, formalin-fixed paraffin-embedded; POU2AF1, POU domain class 2-associating factor 1;
PR, partial response; SD, stable disease.
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Extended Data Fig. 3 | See next page for caption.
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Extended Data Fig. 3 | Overview of Immunoscore index, Immunoscore TCE/TCE+ panels, and Immunoscore SC panel. a,b, Following the pathologist
selection of a digital image area, IHC staining of CD3 and CD8 was quantified by the application of a prespecified bioinformatics algorithm that generated
analysis cutoffs and a numerical index named Immunoscore. Because the majority of lymph node biopsy specimens lacked an identifiable invasive margin,
as expected for lymphoma, cell densities were calculated from the core tumour only. a, Representative images (250- and 1000-µm scales) of CD3 and
CD8 T-cell densities (low, medium, or high) in tumour biopsy specimens. b, Representative images (50- µm scale) of CD3 and CD8 T-cell densities in
patients with a high (top panels) or low (bottom panels) Immunoscore index. c,d, Representative images (250-µm scale) of successive stainings with
Immunoscore TCE (c) and Immunoscore SC (d) panels of tumour biopsy specimens from patients in ZUMA-1 with CR (top panels) or without CR (bottom
panels). e, Representative images (50-µm scale) of stainings with Immunoscore TCE+ panel of tumour biopsy specimens. One staining per sample per
marker. EZH2, enhancer of zeste homolog 2; FOXP3, forkhead box P3; H&E, haematoxylin and eosin; IHC, immunohistochemistry; LAG-3, lymphocyteactivation gene 3; LOX-1, lectin-type oxidised LDL receptor 1; PD-1, programmed cell death protein 1; SC, Suppressive Cell; TCE, T-cell Exhaustion; TIM-3,
T-cell immunoglobulin and mucin domain 3; TOX, thymocyte selection–associated high mobility group box.
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Extended Data Fig. 4 | See next page for caption.
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Extended Data Fig. 4 | Overview of Immunoscore TCE+ panel. a, Representative images (50-µm scale; 40× magnification) of staining with Immunoscore
TCE+ panel of ZUMA-1 tumour biopsy specimens from patients with ongoing CR versus relapse after PR, at pre- (top panels) and posttreatment (bottom
panels). b, Representative images (50-µm scale; 40× magnification) of cell phenotyping with Immunoscore TCE+ panel in ZUMA-1 tumour biopsy
specimens. Arrows point to helper T-cells (CD3+CD8–PD-1+LAG-3+TIM-3–FoxP3–TOX–EZH2+), cytotoxic T-cells (CD3+CD8+PD-1+LAG-3–TIM3+FoxP3–TOX–EZH2+), regulatory T-cells (CD3+CD8–PD-1+LAG-3+/–TIM-3–FoxP3+TOX–EZH2+), exhausted helper T-cells (CD3+CD8–PD-1+LAG3+TIM-3–FoxP3–TOX+EZH2+), and tumour cells (EZH2+CD3–). One staining per sample per marker. axi-cel, axicabtagene ciloleucel; CR, complete
response; EZH2, enhancer of zeste homolog 2; FOXP3, forkhead box P3; LAG-3, lymphocyte-activation gene 3; PD-1, programmed cell death protein 1; PR,
partial response; TCE, T-cell Exhaustion; TIM-3, T-cell immunoglobulin and mucin domain 3; TOX, thymocyte selection-associated high mobility group
box.

Nature Medicine | www.nature.com/naturemedicine

Nature Medicine

Extended Data Fig. 5 | See next page for caption.
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Extended Data Fig. 5 | Correlative analyses with Immunoscore panels. a,b, Correlations of CD3+ (a) and CD8+ (b) T-cell densities measured with
Immunoscore TL (X-axis) versus Immunoscore TCE (Y-axis) panels in ZUMA-1 patient biopsies at pretreatment (subset 1, n = 19). The grey ribbons
represent the 95% Confidence Interval of the regression line. c, Correlation between cell phenotypes measured with Immunoscore TCE (X-axis) versus
Immunoscore TCE+ (Y-axis) panels in two adjacent tissue slides (1 slide per panel) from ZUMA-1 patient biopsies (subset 1, n = 8). Statistical significance
of the spearman coefficient level (two-sided P value) as shown. d, Association between cell densities of tumour-infiltrating immune subsets (T-cells
or myeloid cells, as indicated) and Immunoscore index (low versus high) in ZUMA-1 patient biopsies (subset 1, n = 24 and n = 18, respectively). Twosided Wilcoxon test, p values as shown. ABC, activated B-cell DLBCL subtype; DLBCL, diffuse large B-cell lymphoma; GCB, germinal centre B-cell DLBCL
subtype; LAG-3, lymphocyte-activation gene 3; IC, immune checkpoint; M-MDSC, monocytic myeloid-derived suppressor cell; PD-1, programmed cell
death protein 1; PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; Tc, cytotoxic T-cell; TCE, T-cell Exhaustion; Th, helper T-cell; TIM-3,
T-cell immunoglobulin and mucin domain 3; Treg, regulatory T-cell.
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Extended Data Fig. 6 | Correlative studies of Immunosign 21 score with cell subsets across 3 independent datasets. a, Definition of the Immunosign
21 score cutoff. The Immunosign 21 scoring function is an algorithm derived from the Immunoscore algorithm, is independent of clinical outcome, and
is predefined as the 25th percentile of the observed scores among samples. b-d, Correlation of Immunosign 21 (low versus high) with cell subsets in 3
independent datasets (Two-sided Wilcoxon test). b,c, Immunosign 21 correlations with cell subset densities analysed by Immunoscore TCE/TCE+ panels
in b, ZUMA-1 pretreatment tumour biopsy specimens from third line, r/r DLBCL patients (subset 1, n = 22 for T-cell subsets; n = 15 for myeloid subsets)
and c, DLBCL biopsy specimens at diagnosis from treatment-naïve patients (n = 67). d, Immunosign 21 correlations with normalised gene expression of
T-cells or of myeloid cells analysed by IO360 NanoString panel in pretreatment tumour biopsy specimens from second line DLBCL patients (n = 252). The
number of samples per group is indicated on each panel. DLBCL, diffuse large B-cell lymphoma; FOXP3, forkhead box P3; LAG-3, lymphocyte-activation
gene 3; M-MDSC, monocytic myeloid-derived suppressor cell; PD-1, programmed cell death protein 1; PMN-MDSC, polymorphonuclear myeloid-derived
suppressor cell; SC, Suppressive cell; TCE, T-cell Exhaustion; TIM-3, T-cell immunoglobulin and mucin domain 3; Treg, regulatory T-cell.
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Extended Data Fig. 7 | See next page for caption.
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Extended Data Fig. 7 | Circulating peak CAR T-cell levels normalised to pretreatment tumour burden correlated to Immunoscore. T-cell densities
were measured with Immunoscore TCE+ panel in ZUMA-1 patient biopsies, 7 to 14 days after axi-cel infusion (Subset 2, n = 18). Tc (left panels) and Th
(right panels) phenotypes were classified by checkpoint expression (PD-1+/–, LAG-3+/–, TIM-3+/–, TOX+/–). The grey ribbon represents the 95%
Confidence Interval of the regression line. Statistical significance of the spearman coefficient level (two-sided P values) were calculated and significant
p values (< 0.05) are shown in red squares. From top to bottom: all phenotypes (any checkpoint), 0 IC (no checkpoint), 1 IC (any 1 checkpoint: PD-1 or
LAG-3 or TIM-3 or TOX), 2 IC (any 2 checkpoints: PD-1+/LAG-3+ or PD-1+/TIM-3+ or PD-1+/TOX+ or LAG-3+/TIM-3+ or LAG-3+/TOX+ or TIM-3+/
TOX+), 3 IC (any 3 checkpoints: PD-1+LAG-3+TIM-3+ or PD-1+LAG-3+TOX+ or LAG-3+TIM-3+TOX+), 4 IC (all 4 checkpoints: PD-1+LAG-3+TIM3+TOX+), TOX+ (TOX+ in combination with any checkpoint(s): TOX+PD-1+/–LAG-3+/–TIM-3+/–), TOX– (any combination of checkpoint(s) without
TOX: TOX–PD-1+/–LAG-3+/–TIM-3+/–), and TOX only (TOX+PD-1–LAG-3–TIM-3–). axi-cel, axicabtagene ciloleucel; CAR, chimeric antigen receptor;
LAG-3, lymphocyte-activation gene 3; IC, immune checkpoint; PD-1, programmed cell death protein 1; Tc, cytotoxic T-cell; Th, helper T-cell; TIM-3, T-cell
immunoglobulin and mucin domain 3; TME, tumour microenvironment; TOX, thymocyte selection–associated high mobility group box.
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Extended Data Fig. 8 | See next page for caption.
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Extended Data Fig. 8 | Evolution of immune gene expression in tumour biopsies of ZUMA-1 patients who relapsed. Gene expression was measured with
PanCancer Immune Profiling panel in tumour biopsies from unpaired or paired samples (as indicated) of Zuma 1 patients from subset 1 (n=39; 19 unpaired
FFPE; 23 unpaired FF; 3 paired FF), subset 2 (n=22; 14 unpaired FFPE; 12 unpaired FF; 3 paired FF), and subset 3 (n=4; 2 unpaired FFPE; 3 unpaired FF; 3
paired FF,). a-c, Gene expression related to anti-tumour immune response. a, Cytotoxic T-cell–related genes; b, cytokine and IFN-related genes; c, MHC
class I–related genes. P values were derived with a Kruskal-Wallis test. d-i, Gene expression related to immunosuppressive response. d, Comparative
gene expression of FoxP3, CTLA-4, CCR4, and CCL22 genes (Kruskal-Wallis test; P values as indicated) in biopsies from subset 1 (n = 19), subset 2 (n =
14), and subset 3 (n = 2); e-i, Ratios of gene expression for CTLA-4 with (e) CD3D or (f) CD3E (statistical significance of the spearman coefficient level
(two-sided P value) embedded in panels; grey ribbons represent the 95% Confidence Interval of the regression line) and of FoxP3 with (g) CD3D, (h)
CD3E, or (i) CD8A (Kruskal-Wallis test, P values as indicated). j,k, Correlations between gene expression of CCL22 and cell density of Treg measured
by Immunoscore TCE panel (j) or gene expression of CCR4 (k) in tumour biopsies from Zuma 1 subset 1 pts (n = 14 and n = 16, respectively),two-sided
Wilcoxon tests. axi-cel, axicabtagene ciloleucel; CCL, chemokine ligand; CCR, chemokine receptor; CTLA-4, cytotoxic T lymphocyte–associated protein
4; FOXP3, forkhead box P3; GZMA, granzyme A; HLA, human leucocyte antigen; IL, interleukin; IRF1, interferon regulatory factor 1; LAG-3, lymphocyteactivation gene 3; MHC, major histocompatibility complex; TCE, T-cell Exhaustion; TME, tumour microenvironment; Treg, regulatory T-cell.
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Extended Data Fig. 9 | B-cell lineage and CTA gene expression in tumour biopsies of ZUMA-1 patients. Gene expression was measured with PanCancer
Immune Profiling panel in Zuma 1 (a,b) tumour biopsies from subsets 1, 2, and 3, and (c,d) in pretreatment tumour biopsies from patients with CR (n=22
total [20 CR, 2 PR]) vs. nonCR (n=7 total [4 SD, 3 PD]) a, Volcano plots of B-cell lineage (top panel) and CTA (bottom panel) gene expression from subset
2 (n = 12) and subset 3 (n = 3). The plot was constructed using log2(fold change) and –log10(P value) for all genes analysed by PanCancer Immune
Profiling panel. Red dots represent the top differentially expressed genes with P<0.01 (two-sided t.test without adjustment). b, Evolution of B-cell and
CTA gene expression across FFPE biopsies from subsets 1 (n=19), 2 (n=14), and 3 (n=2). c, Volcano plots of B-cell lineage (left) and CTA-related (right)
gene expression in pretreatment tumour biopsies of patients with CR vs. nonCR outcomes. P values were derived with a Kruskal-Wallis test. d, Gene
expression of CTA-related genes (MAGE-B2 and PRAME) in pretreatment tumour biopsies of patients with CR/PR vs. SD/PD outcomes. P values were
derived with two-sided Wilcoxon test.AICDA, activation-induced cytidine deaminase; axi-cel, axicabtagene ciloleucel; BTK, Bruton tyrosine kinase; CR,
complete response; CTA, cancer testis antigen; FFPE, formalin-fixed paraffin-embedded; IKBKB, inhibitor of nuclear factor kappa B kinase subunit B; ; IS21,
Immunosign21; MAGE, melanoma-associated antigen; PAX5, paired box protein 5; PD, progressive disease; POU2AF1, POU domain class 2-associating
factor 1; PR, partial response; PRAME, preferentially expressed antigen in melanoma; SAA1, serum amyloid A1; SD, stable disease; TME, tumour
microenvironment.
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Extended Data Fig. 10 | Correlative studies in Zuma 1 and commercial axi-cel patient datasets. a,b,d. Pretreatment tumour biopsies from commercial
patients (r/r DLBCL) were analysed with IO360 NanoString panel (n=33; 20 CR and 10 non-CR; 3 samples failed nanostring QC). a, Correlation matrix for
myeloid-secreted and/or T-cell–produced cytokine/chemokines (horizontal axis) with T-cell subset–related genes (vertical axis) (Spearman R). The scale
bar (-1 to 1) represents the R value. b, Gene expression correlation of CCL5 chemokine and cytotoxic T-cells–produced serine protease GZMA. Statistical
significance of the spearman coefficient level (two-sided P value) in the panels. The grey ribbon represents the 95% Confidence Interval of the regression
line. c,d. Comparison of regulation of three functional pathways (“Positive regulation of leukocyte cell-cell adhesion", "Lymphocyte costimulation",
and "Antigen processing and peptide antigen presentation") in pretreatment, CR vs. non-CR, tumour biopsies from Zuma 1 (c, 20 CR, 9 non-CR) and
commercial (d, 20 CR, 10 non-CR) patients. Functional pathways with statistically significant p values < 0.005 were selected and GSEA adjusted p.values
were calculated with Benjamini-Hochberg method. Adjusted two-sided p.values of less than 0.5 in at least one of the two panels are shown. axi-cel,
axicabtagene ciloleucel; CCL, chemokine ligand; CXCL, chemokine C-X-C motif ligand; DLBCL, diffuse large B-cell lymphoma; CR, complete response;
non-CR, non-complete response; FoxP3, forkhead box P3; GNLY, granulysin; GZMA, granzyme A; IL, interleukin; IRF1, interferon regulatory factor 1; QC,
quality control; r/r, relapse, refractory; STAT, signal transducer and activator of transcription; TNFRSF14, tumour necrosis factor receptor.
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